MariMed (MRMD) CCO converts 32,813 RSUs, 11,370 shares withheld for tax
Rhea-AI Filing Summary
MARIMED INC. Chief Commercial Officer Ryan Crandall reported RSU vesting and related tax withholding on July 15, 2026. He converted 32,813 Restricted Stock Units into common stock and had 11,370 shares withheld to cover taxes, leaving 1,124,246 common shares and 98,437 RSUs held directly. Remaining RSUs vest in three equal installments through April 15, 2027, and the transactions were not made under a Rule 10b5-1 plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
32,813 shares exercised/converted
Mixed
3 txns
Insider
Crandall Ryan
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units (RSU) | 32,813 | $0.00 | -- |
| Exercise | Common stock | 32,813 | $0.00 | -- |
| Tax Withholding | Common stock | 11,370 | $0.0662 | $752.69 |
Holdings After Transaction:
Restricted Stock Units (RSU) — 98,437 shares (Direct);
Common stock — 1,135,616 shares (Direct)
Footnotes (1)
- RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest in three equal installments on each of October 15, 2026, January 15, 2027 and April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Key Figures
Shares acquired via RSU conversion: 32,813 shares
Shares withheld for taxes: 11,370 shares
Common shares held after transactions: 1,124,246 shares
+3 more
6 metrics
Shares acquired via RSU conversion
32,813 shares
Restricted Stock Units converting into common stock on 2026-07-15
Shares withheld for taxes
11,370 shares
Common shares withheld to satisfy tax withholding obligations on RSU vesting
Common shares held after transactions
1,124,246 shares
Direct common stock ownership after the tax-withholding disposition
RSUs remaining after conversion
98,437 units
Restricted Stock Units outstanding following the 32,813-unit conversion
Tax withholding price per share
0.0662 per share
Per-share value used for the 11,370-share tax-withholding disposition
Future RSU vesting dates
October 15, 2026; January 15, 2027; April 15, 2027
Scheduled vesting dates for remaining RSUs from the April 15, 2026 grant
Key Terms
Restricted Stock Units (RSU), tax withholding obligations, Rule 10b5-1 plan
3 terms
Restricted Stock Units (RSU) financial
"The security title is listed as Restricted Stock Units (RSU)."
tax withholding obligations financial
"shares of common stock withheld by the Issuer to satisfy tax withholding obligations"
Rule 10b5-1 plan financial
"The transactions were not made under a Rule 10b5-1 plan."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did MariMed (MRMD) report for Ryan Crandall?
MariMed disclosed that Chief Commercial Officer Ryan Crandall vested 32,813 RSUs on July 15, 2026, which converted into common stock. In connection with this vesting, a portion of the resulting shares was withheld to satisfy tax obligations rather than sold on the open market.
What is the future vesting schedule for Ryan Crandall’s remaining MariMed (MRMD) RSUs?
The remaining RSUs from the April 15, 2026 grant vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027. Each vesting date will convert one-third of the outstanding RSUs into MariMed common stock under the award agreement.
Were Ryan Crandall’s MariMed (MRMD) transactions made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox was not selected, meaning these transactions were not reported as being executed under a pre-arranged trading plan. They are instead presented as standard equity compensation and related tax withholding events.